Loading candles…
Suraksha Diagnostic Ltd. was incorporated in 2005 and operates in the healthcare and diagnostics industries. The company provides integrated pathology, radiology testing, and medical consultancy services primarily across East India. Its service offerings include pathology testing, radiology testing, medical consultancy, MRI scans, and CT scans. Suraksha Diagnostic Ltd. focuses on delivering specialized diagnostic solutions through a growing network of centers in the region, playing a significant role in the regional healthcare market. The company does not have listed subsidiaries or ventures and is not listed on any stock exchange.
This page is a live market overview for SURAKSHA DIAGNOSTIC LTD (SURAKSHA) on the NSE. As a listed security, SURAKSHA DIAGNOSTIC LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for SURAKSHA before placing trades on tick2trade.
As of the latest feed, SURAKSHA last traded at ₹249.55 on NSE, down ₹1.2 (0.48%) from the previous close of ₹250.75. Today's session range is ₹247 – ₹253.85, against a 52-week band of ₹224.1 – ₹333. Traded volume today stands at 20.82K shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for SURAKSHA in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether SURAKSHA is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for SURAKSHA DIAGNOSTIC LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in SURAKSHA. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated SURAKSHA option chain page linked from this overview.
| Results - FY25 |
| To consider and approve the financial results for the period ended December 31, 2025 |
| 5 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 10 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 8 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 28 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.